Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Diego Forest Laboratories |
---|---|
Information provided by: | University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00652457 |
To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).
Condition | Intervention | Phase |
---|---|---|
Huntington's Disease |
Drug: Memantine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease" |
Estimated Enrollment: | 60 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Memantine 10 mg BID for three months
|
Drug: Memantine
10 mg BID x 3 months
|
Results of several published clinical trials suggest that memantine has a beneficial effect in dementing conditions, such as Alzheimer's disease; however, the effects of memantine on cognitive and behavioral function in HD are unknown. Our hypotheses are that HD patients who are administered memantine will show improved performance on psychometric tests of memory and executive functions in addition to behavior and that patients treated with memantine will show more improvement after six months than after three months of treatment.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jody Corey-Bloom, MD, PhD | 858-642-3470 | jcoreybl@vapop.ucsd.edu |
Contact: Jody Goldstein, BA | 858-622-5854 | jlgoldstein@ucsd.edu |
United States, California | |
University of California, San Diego | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Jody Corey-Bloom, MD, PhD 858-642-3470 jcoreybl@vapop.ucsd.edu | |
Contact: Jody Goldstein, BA 858-622-5854 jlgoldstein@ucsd.edu | |
Principal Investigator: Jody Corey-Bloom, MD, PhD | |
United States, Kansas | |
University of Kansas Medical Center | Recruiting |
Kansas City, Kansas, United States, 66160 | |
Contact: Richard Dubinsky, MD, MPH rdubinsky@safetyresearch.com | |
Contact: Janice Broyles-Gorman jbroyles-gorman@kumc.edu | |
Principal Investigator: Richard Dubinsky, MD, MPH | |
United States, Maryland | |
Johns Hopkins Hospital | Recruiting |
Baltimore, Maryland, United States, 21287 | |
Contact: Adam Roseblatt, MD 410-955-2398 arosenb3@jhmi.edu | |
Contact: Nadine Yoritomo nyorito1@jhmi.edu | |
Principal Investigator: Adam Rosenblatt, MD |
Responsible Party: | Department of Neurosciences, University of California San Diego ( Jody Corey-Bloom, MD, PhD ) |
Study ID Numbers: | MEM-HD |
Study First Received: | March 31, 2008 |
Last Updated: | March 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00652457 |
Health Authority: | United States: Food and Drug Administration (IND exemption) |
Excitatory Amino Acids Ganglion Cysts Huntington disease Basal Ganglia Diseases Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Dyskinesias Cognition Disorders Chorea |
Dopamine Delirium, Dementia, Amnestic, Cognitive Disorders Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Mental Disorders Movement Disorders Memantine Dementia Huntington Disease Delirium |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Antiparkinson Agents Excitatory Amino Acid Agents Dopamine Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |